<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39411713</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Future applications of host direct therapies for infectious disease treatment.</ArticleTitle><Pagination><StartPage>1436557</StartPage><MedlinePgn>1436557</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1436557</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1436557</ELocationID><Abstract><AbstractText>New and emerging pathogens, such as SARS-CoV2 have highlighted the requirement for threat agnostic therapies. Some antibiotics or antivirals can demonstrate broad-spectrum activity against pathogens in the same family or genus but efficacy can quickly reduce due to their specific mechanism of action and for the ability of the disease causing agent to evolve. This has led to the generation of antimicrobial resistant strains, making infectious diseases more difficult to treat. Alternative approaches therefore need to be considered, which include exploring the utility of Host-Directed Therapies (HDTs). This is a growing area with huge potential but difficulties arise due to the complexity of disease profiles. For example, a HDT given early during infection may not be appropriate or as effective when the disease has become chronic or when a patient is in intensive care. With the growing understanding of immune function, a new generation of HDT for the treatment of disease could allow targeting specific pathways to augment or diminish the host response, dependent upon disease profile, and allow for bespoke therapeutic management plans. This review highlights promising and approved HDTs that can manipulate the immune system throughout the spectrum of disease, in particular to viral and bacterial pathogens, and demonstrates how the advantages of HDT will soon outweigh the potential side effects.</AbstractText><CopyrightInformation>Copyright © 2024 Thom and D’Elia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thom</LastName><ForeName>Ruth E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Chemical, Biological and Radiological Division, Defence Science and Technology Laboratory, Porton Down, Salisbury, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Elia</LastName><ForeName>R V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Strathclyde Institute of Pharmacy &amp; Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">STING</Keyword><Keyword MajorTopicYN="N">host-directed</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">itaconate</Keyword><Keyword MajorTopicYN="N">pyroptosis</Keyword><Keyword MajorTopicYN="N">therapeutic</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39411713</ArticleId><ArticleId IdType="pmc">PMC11473292</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1436557</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. (2015) 20:812–22. doi: 10.1634/theoncologist.2014-0422</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2014-0422</ArticleId><ArticleId IdType="pmc">PMC4492230</ArticleId><ArticleId IdType="pubmed">26069281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. . Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. (2013) 1291:1–13. doi: 10.1111/nyas.12180</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12180</ArticleId><ArticleId IdType="pmc">PMC3910157</ArticleId><ArticleId IdType="pubmed">23772560</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Uzoma I, Moore RT, Gilbert M, Duplantier AJ, Panchal RG. Mitigating the impact of antibacterial drug resistance through host-directed therapies: current progress, outlook, and challenges. mBio. (2018) 9(1):e01932–17. doi: 10.1128/mBio.01932-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01932-17</ArticleId><ArticleId IdType="pmc">PMC5790911</ArticleId><ArticleId IdType="pubmed">29382729</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. . Cytokine storm in A phase 1 trial of the anti-cd28 monoclonal antibody tgn1412. N Engl J Med. (2006) 355:1018–28. doi: 10.1056/NEJMoa063842</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa063842</ArticleId><ArticleId IdType="pubmed">16908486</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. . Interferon-alpha2b treatment for covid-19. Front Immunol. (2020) 11. doi: 10.3389/fimmu.2020.01061</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01061</ArticleId><ArticleId IdType="pmc">PMC7242746</ArticleId><ArticleId IdType="pubmed">32574262</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Z, Wang T, Chen L, Chen X, Li L, Qin X, et al. . The effect of recombinant human interferon alpha nasal drops to prevent covid-19 pneumonia for medical staff in an epidemic area. Curr Top Med Chem. (2021) 21:920–7. doi: 10.2174/1568026621666210429083050</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026621666210429083050</ArticleId><ArticleId IdType="pubmed">33970846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. . Heightened innate immune responses in the respiratory tract of covid-19 patients. Cell Host Microbe. (2020) 27:883–890.E2. doi: 10.1016/j.chom.2020.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7196896</ArticleId><ArticleId IdType="pubmed">32407669</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, et al. . A dynamic covid-19 immune signature includes associations with poor prognosis. Nat Med. (2020) 26:1623–35. doi: 10.1038/s41591-020-1038-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1038-6</ArticleId><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Halabi S, Shiber S, Paz M, Gottlieb TM, Barash E, Navon R, et al. . Host test based on tumor necrosis factor-related apoptosis-inducing ligand, interferon gamma-induced protein-10 and C-reactive protein for differentiating bacterial and viral respiratory tract infections in adults: diagnostic accuracy study. Clin Microbiol Infect. (2023) 29:1159–65. doi: 10.1016/j.cmi.2023.05.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.05.033</ArticleId><ArticleId IdType="pubmed">37270059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukaszewski RA, Jones HE, Gersuk VH, Russell P, Simpson A, Brealey D, et al. . Presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures. Intensive Care Med. (2022) 48:1133–43. doi: 10.1007/s00134-022-06769-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06769-z</ArticleId><ArticleId IdType="pmc">PMC9281215</ArticleId><ArticleId IdType="pubmed">35831640</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, et al. . Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis. (2016) 16:E47–63. doi: 10.1016/S1473-3099(16)00078-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)00078-5</ArticleId><ArticleId IdType="pmc">PMC7164794</ArticleId><ArticleId IdType="pubmed">27036359</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong-James D, Brown GD, Netea MG, Zelante T, Gresnigt MS, Van De Veerdonk FL, et al. . Immunotherapeutic approaches to treatment of fungal diseases. Lancet Infect Dis. (2017) 17:E393–402. doi: 10.1016/S1473-3099(17)30442-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30442-5</ArticleId><ArticleId IdType="pubmed">28774700</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves SM, Ferreira AV, Cunha C, Carvalho A. Targeting immunometabolism in host-directed therapies to fungal disease. Clin Exp Immunol. (2022) 208:158–66. doi: 10.1093/cei/uxab014</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cei/uxab014</ArticleId><ArticleId IdType="pmc">PMC9188340</ArticleId><ArticleId IdType="pubmed">35641161</ArticleId></ArticleIdList></Reference><Reference><Citation>Varikuti S, Jha BK, Volpedo G, Ryan NM, Halsey G, Hamza OM, et al. . Host-directed drug therapies for neglected tropical diseases caused by protozoan parasites. Front Microbiol. (2018) 9. doi: 10.3389/fmicb.2018.02655</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.02655</ArticleId><ArticleId IdType="pmc">PMC6284052</ArticleId><ArticleId IdType="pubmed">30555425</ArticleId></ArticleIdList></Reference><Reference><Citation>Adderley J, Grau GE. Host-directed therapies for malaria: possible applications and lessons from other indications. Curr Opin Microbiol. (2023) 71:102228. doi: 10.1016/j.mib.2022.102228</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2022.102228</ArticleId><ArticleId IdType="pubmed">36395572</ArticleId></ArticleIdList></Reference><Reference><Citation>Latinovic OS, Reitz M, Heredia A. Ccr5 inhibitors and hiv-1 infection. J AIDS HIV Treat. (2019) 1:1–5. doi: 10.33696/AIDS.1.001</Citation><ArticleIdList><ArticleId IdType="doi">10.33696/AIDS.1.001</ArticleId><ArticleId IdType="pmc">PMC6693856</ArticleId><ArticleId IdType="pubmed">31414081</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollard SM, Kanmogne GD. Maraviroc: A review of its use in hiv infection and beyond. Drug Des Devel Ther. (2015) 9:5447–68. doi: 10.2147/DDDT.S90580</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S90580</ArticleId><ArticleId IdType="pmc">PMC4598208</ArticleId><ArticleId IdType="pubmed">26491256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng D, Han B, Zhang W, Wu W. Clinical effects of ntcp-inhibitor myrcludex B. J Viral Hepat. (2021) 28:852–8. doi: 10.1111/jvh.13490</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.13490</ArticleId><ArticleId IdType="pubmed">33599010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. . Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of A phase ib/iia study. J Hepatol. (2016) 65:490–8. doi: 10.1016/j.jhep.2016.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2016.04.016</ArticleId><ArticleId IdType="pubmed">27132170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lempp FA, Urban S. Inhibitors of hepatitis B virus attachment and entry. Intervirology. (2014) 57:151–7. doi: 10.1159/000360948</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000360948</ArticleId><ArticleId IdType="pubmed">25034482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, et al. . Ebola viral glycoprotein bound to its endosomal receptor niemann-pick C1. Cell. (2016) 164:258–68. doi: 10.1016/j.cell.2015.12.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.044</ArticleId><ArticleId IdType="pmc">PMC7111281</ArticleId><ArticleId IdType="pubmed">26771495</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulseberg CE, Fénéant L, Szymanska KM, White JM. Lamp1 increases the efficiency of lassa virus infection by promoting fusion in less acidic endosomal compartments. mBio. (2018) 9(1):e01818–17. doi: 10.1128/mBio.01818-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01818-17</ArticleId><ArticleId IdType="pmc">PMC5750398</ArticleId><ArticleId IdType="pubmed">29295909</ArticleId></ArticleIdList></Reference><Reference><Citation>Salata C, Calistri A, Alvisi G, Celestino M, Parolin C, Palù G. Ebola virus entry: from molecular characterization to drug discovery. Viruses. (2019) 11(3):274. doi: 10.3390/v11030274</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11030274</ArticleId><ArticleId IdType="pmc">PMC6466262</ArticleId><ArticleId IdType="pubmed">30893774</ArticleId></ArticleIdList></Reference><Reference><Citation>Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, et al. . A systematic screen of fda-approved drugs for inhibitors of biological threat agents. PloS One. (2013) 8:E60579. doi: 10.1371/journal.pone.0060579</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060579</ArticleId><ArticleId IdType="pmc">PMC3618516</ArticleId><ArticleId IdType="pubmed">23577127</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanesi L, Petrillo M, Sepe L, Boccia A, D’agostino N, Passamano M, et al. . Systematic analysis of human kinase genes: A large number of genes and alternative splicing events result in functional and structural diversity. BMC Bioinf. (2005) 6 Suppl 4:S20. doi: 10.1186/1471-2105-6-S4-S20</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-6-S4-S20</ArticleId><ArticleId IdType="pmc">PMC1866387</ArticleId><ArticleId IdType="pubmed">16351747</ArticleId></ArticleIdList></Reference><Reference><Citation>Meineke R, Rimmelzwaan GF, Elbahesh H. Influenza virus infections and cellular kinases. Viruses. (2019) 11(2):171. doi: 10.3390/v11020171</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11020171</ArticleId><ArticleId IdType="pmc">PMC6410056</ArticleId><ArticleId IdType="pubmed">30791550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Sharma NR, Ly H, Parslow TG, Liang Y. Receptor tyrosine kinase inhibitors that block replication of influenza A and other viruses. Antimicrob Agents Chemother. (2011) 55:5553–9. doi: 10.1128/AAC.00725-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00725-11</ArticleId><ArticleId IdType="pmc">PMC3232778</ArticleId><ArticleId IdType="pubmed">21930873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther. (2018) 18:1249–70. doi: 10.1080/14737140.2018.1527688</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737140.2018.1527688</ArticleId><ArticleId IdType="pmc">PMC6322661</ArticleId><ArticleId IdType="pubmed">30259761</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wispelaere M, Lacroix AJ, Yang PL. The small molecules azd0530 and dasatinib inhibit dengue virus rna replication via fyn kinase. J Virol. (2013) 87:7367–81. doi: 10.1128/JVI.00632-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00632-13</ArticleId><ArticleId IdType="pmc">PMC3700292</ArticleId><ArticleId IdType="pubmed">23616652</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagno V, Magliocco G, Tapparel C, Daali Y. The tyrosine kinase inhibitor nilotinib inhibits sars-cov-2 in vitro . Basic Clin Pharmacol Toxicol. (2021) 128:621–4. doi: 10.1111/bcpt.13537</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.13537</ArticleId><ArticleId IdType="pmc">PMC7753569</ArticleId><ArticleId IdType="pubmed">33232578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, et al. . Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in sars-cov-2-infected rhesus macaques. Cell. (2021) 184 460-475:E21. doi: 10.1016/j.cell.2020.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7654323</ArticleId><ArticleId IdType="pubmed">33278358</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik RR, Shakya AK, Aladwan SM, El-Tanani M. Kinase inhibitors as potential therapeutic agents in the treatment of covid-19. Front In Pharmacol. (2022) 13. doi: 10.3389/fphar.2022.806568</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.806568</ArticleId><ArticleId IdType="pmc">PMC9014181</ArticleId><ArticleId IdType="pubmed">35444538</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaker SK, Ch’ng J, Christofk HR. Viral hijacking of cellular metabolism. BMC Biol. (2019) 17:59. doi: 10.1186/s12915-019-0678-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-019-0678-9</ArticleId><ArticleId IdType="pmc">PMC6637495</ArticleId><ArticleId IdType="pubmed">31319842</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Acebes MA, Vazquez-Calvo A, Saiz JC. Lipids and flaviviruses, present and future perspectives for the control of dengue, zika, and west nile viruses. Prog Lipid Res. (2016) 64:123–37. doi: 10.1016/j.plipres.2016.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2016.09.005</ArticleId><ArticleId IdType="pubmed">27702593</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu J, Xing C, Du Y, Duan T, Liu S, Zhang P, et al. . Pharmacological inhibition of fatty acid synthesis blocks sars-cov-2 replication. Nat Metab. (2021) 3:1466–75. doi: 10.1038/s42255-021-00479-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-021-00479-4</ArticleId><ArticleId IdType="pmc">PMC8475461</ArticleId><ArticleId IdType="pubmed">34580494</ArticleId></ArticleIdList></Reference><Reference><Citation>Baindara P. Host-directed therapies to combat tuberculosis and associated non-communicable diseases. Microb Pathog. (2019) 130:156–68. doi: 10.1016/j.micpath.2019.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2019.03.003</ArticleId><ArticleId IdType="pubmed">30876870</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida PE, Silva AR, Maya-Monteiro CM, Torocsik D, D’avila H, Dezso B, et al. . Mycobacterium bovis bacillus calmette-guerin infection induces tlr2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis. J Immunol. (2009) 183:1337–45. doi: 10.4049/jimmunol.0900365</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900365</ArticleId><ArticleId IdType="pubmed">19561094</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi H. Immunometabolism at the intersection of metabolic signaling, cell fate, and systems immunology. Cell Mol Immunol. (2022) 19:299–302. doi: 10.1038/s41423-022-00840-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-022-00840-x</ArticleId><ArticleId IdType="pmc">PMC8891332</ArticleId><ArticleId IdType="pubmed">35190684</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, et al. . Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc Natl Acad Sci U.S.A. (2013) 110:7820–5. doi: 10.1073/pnas.1218599110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218599110</ArticleId><ArticleId IdType="pmc">PMC3651434</ArticleId><ArticleId IdType="pubmed">23610393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, et al. . Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab. (2016) 24:158–66. doi: 10.1016/j.cmet.2016.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.06.004</ArticleId><ArticleId IdType="pmc">PMC5108454</ArticleId><ArticleId IdType="pubmed">27374498</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuk JM, Park EJ, Kim IS, Jo EK. Itaconate family-based host-directed therapeutics for infections. Front Immunol. (2023) 14:1203756. doi: 10.3389/fimmu.2023.1203756</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1203756</ArticleId><ArticleId IdType="pmc">PMC10228716</ArticleId><ArticleId IdType="pubmed">37261340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Fok Lung T, Charytonowicz D, Beaumont KG, Shah SS, Sridhar SH, Gorrie CL, et al. . Klebsiella pneumoniae induces host metabolic stress that promotes tolerance to pulmonary infection. Cell Metab. (2022) 34:761–774.E9. doi: 10.1016/j.cmet.2022.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2022.03.009</ArticleId><ArticleId IdType="pmc">PMC9081115</ArticleId><ArticleId IdType="pubmed">35413274</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson KL, Lung TWF, Dach F, Annavajhala MK, Gabryszewski SJ, Groves RA, et al. . Staphylococcus aureus induces an itaconate-dominated immunometabolic response that drives biofilm formation. Nat Commun. (2021) 12(1):1399. doi: 10.1038/s41467-021-21718-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21718-y</ArticleId><ArticleId IdType="pmc">PMC7930111</ArticleId><ArticleId IdType="pubmed">33658521</ArticleId></ArticleIdList></Reference><Reference><Citation>Riquelme SA, Liimatta K, Wong Fok Lung T, Fields B, Ahn D, Chen D, et al. . Pseudomonas aeruginosa utilizes host-derived itaconate to redirect its metabolism to promote biofilm formation. Cell Metab. (2020) 31:1091–1106. E6. doi: 10.1016/j.cmet.2020.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7272298</ArticleId><ArticleId IdType="pubmed">32428444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannister S, Messina NL, Novakovic B, Curtis N. The emerging role of epigenetics in the immune response to vaccination and infection: A systematic review. Epigenetics. (2020) 15:555–93. doi: 10.1080/15592294.2020.1712814</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15592294.2020.1712814</ArticleId><ArticleId IdType="pmc">PMC7574386</ArticleId><ArticleId IdType="pubmed">31914857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. (2011) 3:166–79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056563</ArticleId><ArticleId IdType="pubmed">21416059</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discovery. (2007) 6:21–2. doi: 10.1038/nrd2227</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2227</ArticleId><ArticleId IdType="pubmed">17269160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariffin JK, Das Gupta K, Kapetanovic R, Iyer A, Reid RC, Fairlie DP, et al. . Histone deacetylase inhibitors promote mitochondrial reactive oxygen species production and bacterial clearance by human macrophages. Antimicrob Agents Chemother. (2015) 60:1521–9. doi: 10.1128/AAC.01876-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01876-15</ArticleId><ArticleId IdType="pmc">PMC4775968</ArticleId><ArticleId IdType="pubmed">26711769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha SD, Reid C, Meshkibaf S, Kim SO. Inhibition of interleukin 1beta (Il-1beta) expression by anthrax lethal toxin (Letx) is reversed by histone deacetylase 8 (Hdac8) inhibition in murine macrophages. J Biol Chem. (2016) 291:8745–55. doi: 10.1074/jbc.M115.695809</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.695809</ArticleId><ArticleId IdType="pmc">PMC4861443</ArticleId><ArticleId IdType="pubmed">26912657</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennini ME, Pai RK, Schultz DC, Boom WH, Harding CV. Mycobacterium tuberculosis 19-kda lipoprotein inhibits ifn-gamma-induced chromatin remodeling of mhc2ta by tlr2 and mapk signaling. J Immunol. (2006) 176:4323–30. doi: 10.4049/jimmunol.176.7.4323</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.7.4323</ArticleId><ArticleId IdType="pubmed">16547269</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond B, Batsche E, Boutillon F, Wu YZ, Leduc D, Balloy V, et al. . Anthrax lethal toxin impairs il-8 expression in epithelial cells through inhibition of histone H3 modification. PloS Pathog. (2009) 5:E1000359. doi: 10.1371/journal.ppat.1000359</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000359</ArticleId><ArticleId IdType="pmc">PMC2655721</ArticleId><ArticleId IdType="pubmed">19343203</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SJ, Shin YS, Kang BW, Kim JG, Won KJ, Lieberman PM, et al. . Dna hypermethylation induced by epstein-barr virus in the development of epstein-barr virus-associated gastric carcinoma. Arch Pharm Res. (2017) 40:894–905. doi: 10.1007/s12272-017-0939-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-017-0939-5</ArticleId><ArticleId IdType="pubmed">28779374</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney DG, Kennedy EM, Dumm RE, Bogerd HP, Tsai K, Heaton NS, et al. . Epitranscriptomic enhancement of influenza A virus gene expression and replication. Cell Host Microbe. (2017) 22 377-386:E5. doi: 10.1016/j.chom.2017.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2017.08.004</ArticleId><ArticleId IdType="pmc">PMC5615858</ArticleId><ArticleId IdType="pubmed">28910636</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs A, Burke DC. Viral interference and interferon. Br Med Bull. (1959) 15:185–8. doi: 10.1093/oxfordjournals.bmb.a069760</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.bmb.a069760</ArticleId><ArticleId IdType="pubmed">13853040</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The swedish study group. Lancet. (1998) 351:83–7. doi: 10.1016/S0140-6736(97)06088-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(97)06088-1</ArticleId><ArticleId IdType="pubmed">9439491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Jr., Falloon J, et al. . Increases in cd4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med. (1995) 332:567–75. doi: 10.1056/NEJM199503023320904</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199503023320904</ArticleId><ArticleId IdType="pubmed">7646637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, et al. . Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in covid-19 patients. Cell Host Microbe. (2020) 28:455–464.E2. doi: 10.1016/j.chom.2020.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.07.005</ArticleId><ArticleId IdType="pmc">PMC7368656</ArticleId><ArticleId IdType="pubmed">32707096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Sharma S, Kumar R, Tripathi BN, Barua S, Ly H, et al. . Host-directed antiviral therapy. Clin Microbiol Rev. (2020) 33(3):e00168–19. doi: 10.1128/CMR.00168-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00168-19</ArticleId><ArticleId IdType="pmc">PMC7227448</ArticleId><ArticleId IdType="pubmed">32404434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. (2018) 17:35–56. doi: 10.1038/nrd.2017.162</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.162</ArticleId><ArticleId IdType="pmc">PMC7097079</ArticleId><ArticleId IdType="pubmed">28935918</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N, Valdes-Quintana M, Milanes-Virelles MT, Carbonell D, et al. . Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: A pilot study. BMC Infect Dis. (2004) 4:44. doi: 10.1186/1471-2334-4-44</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-4-44</ArticleId><ArticleId IdType="pmc">PMC529257</ArticleId><ArticleId IdType="pubmed">15500691</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer. J Interferon Cytokine Res. (2019) 39:6–21. doi: 10.1089/jir.2018.0019</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2018.0019</ArticleId><ArticleId IdType="pmc">PMC6350412</ArticleId><ArticleId IdType="pubmed">29889594</ArticleId></ArticleIdList></Reference><Reference><Citation>Deckers J, Anbergen T, Hokke AM, De Dreu A, Schrijver DP, De Bruin K, et al. . Engineering cytokine therapeutics. Nat Rev Bioeng. (2023) 1:286–303. doi: 10.1038/s44222-023-00030-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44222-023-00030-y</ArticleId><ArticleId IdType="pmc">PMC9933837</ArticleId><ArticleId IdType="pubmed">37064653</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton RA, Glassman CR, Garcia KC. Emerging principles of cytokine pharmacology and therapeutics. Nat Rev Drug Discovery. (2023) 22:21–37. doi: 10.1038/s41573-022-00557-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00557-6</ArticleId><ArticleId IdType="pmc">PMC10292932</ArticleId><ArticleId IdType="pubmed">36131080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez A, Patil NK, Stothers CL, Luan L, Mcbride MA, Owen AM, et al. . Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection. Pharmacol Res. (2019) 150:104502. doi: 10.1016/j.phrs.2019.104502</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.104502</ArticleId><ArticleId IdType="pmc">PMC6884699</ArticleId><ArticleId IdType="pubmed">31689522</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilu D, Sauder DN. Imiquimod: modes of action. Br J Dermatol. (2003) 149 Suppl 66:5–8. doi: 10.1046/j.0366-077x.2003.05628.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0366-077x.2003.05628.x</ArticleId><ArticleId IdType="pubmed">14616337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahid A, Ismail H, Li B, Jin T. Molecular and structural basis of dna sensors in antiviral innate immunity. Front Immunol. (2020) 11:613039. doi: 10.3389/fimmu.2020.613039</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.613039</ArticleId><ArticleId IdType="pmc">PMC7734173</ArticleId><ArticleId IdType="pubmed">33329609</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy C, Bowie AG. Recent insights into innate immune nucleic acid sensing during viral infection. Curr Opin Immunol. (2022) 78:102250. doi: 10.1016/j.coi.2022.102250</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102250</ArticleId><ArticleId IdType="pubmed">36209576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong LZ, Kim SM, Wang C, Lee SY, Oh SC, Lee S, et al. . Understanding nucleic acid sensing and its therapeutic applications. Exp Mol Med. (2023) 55:2320–31. doi: 10.1038/s12276-023-01118-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-023-01118-6</ArticleId><ArticleId IdType="pmc">PMC10689850</ArticleId><ArticleId IdType="pubmed">37945923</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbs N, Burnaevskiy N, Chen D, Gonugunta VK, Alto NM, Yan N. Sting activation by translocation from the er is associated with infection and autoinflammatory disease. Cell Host Microbe. (2015) 18:157–68. doi: 10.1016/j.chom.2015.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4537353</ArticleId><ArticleId IdType="pubmed">26235147</ArticleId></ArticleIdList></Reference><Reference><Citation>Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, et al. . The cgas-sting pathway drives type I ifn immunopathology in covid-19. Nature. (2022) 603:145–51. doi: 10.1038/s41586-022-04421-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04421-w</ArticleId><ArticleId IdType="pmc">PMC8891013</ArticleId><ArticleId IdType="pubmed">35045565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou L, Zhang A, Cheng Y, Chen Y. The cgas-sting pathway: A promising immunotherapy target. Front Immunol. (2021) 12:795048. doi: 10.3389/fimmu.2021.795048</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.795048</ArticleId><ArticleId IdType="pmc">PMC8695770</ArticleId><ArticleId IdType="pubmed">34956229</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb LG, Fernandez-Sesma A. Rna viruses and the cgas-sting pathway: reframing our understanding of innate immune sensing. Curr Opin Virol. (2022) 53:101206. doi: 10.1016/j.coviro.2022.101206</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2022.101206</ArticleId><ArticleId IdType="pubmed">35180533</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries F, Shmuel-Galia L, Jiang Z, Wilson R, Landis P, Ng SL, et al. . A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection. Sci Immunol. (2021) 6(59):eabi9002. doi: 10.1126/sciimmunol.abi9002</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abi9002</ArticleId><ArticleId IdType="pmc">PMC8158975</ArticleId><ArticleId IdType="pubmed">34010139</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward A better understanding of complex mechanisms. Cell Discov. (2020) 6:36. doi: 10.1038/s41421-020-0167-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0167-x</ArticleId><ArticleId IdType="pmc">PMC7280307</ArticleId><ArticleId IdType="pubmed">32550001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Li G. Mechanisms and therapeutic regulation of pyroptosis in inflammatory diseases and cancer. Int J Mol Sci. (2020) 21(4):1456. doi: 10.3390/ijms21041456</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21041456</ArticleId><ArticleId IdType="pmc">PMC7073143</ArticleId><ArticleId IdType="pubmed">32093389</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnani L, Colantuoni M, Mortellaro A. Gasdermins: new therapeutic targets in host defense, inflammatory diseases, and cancer. Front Immunol. (2022) 13:898298. doi: 10.3389/fimmu.2022.898298</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.898298</ArticleId><ArticleId IdType="pmc">PMC9285118</ArticleId><ArticleId IdType="pubmed">35844522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Deobald K, Re F. Gasdermin D protects from melioidosis through pyroptosis and direct killing of bacteria. J Immunol. (2019) 202:3468–73. doi: 10.4049/jimmunol.1900045</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1900045</ArticleId><ArticleId IdType="pmc">PMC6548608</ArticleId><ArticleId IdType="pubmed">31036765</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo A, Ranjbar S, De Lacerda LB, Lewandrowski M, Ingber J, et al. . Fcgammar-mediated sars-cov-2 infection of monocytes activates inflammation. Nature. (2022) 606:576–84. doi: 10.1038/s41586-022-04702-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai Q, Yu S, Zhong Y, Lu Z, Qiu C, Yu Y, et al. . A bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin. Science. (2022) 378:Eabq0132. doi: 10.1126/science.abq0132</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq0132</ArticleId><ArticleId IdType="pubmed">36227980</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y, Wang X, Deng Y, Li S, Xu X, Qin Y, et al. . Pyroptosis provides new strategies for the treatment of cancer. J Cancer. (2023) 14:140–51. doi: 10.7150/jca.77965</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.77965</ArticleId><ArticleId IdType="pmc">PMC9809330</ArticleId><ArticleId IdType="pubmed">36605484</ArticleId></ArticleIdList></Reference><Reference><Citation>Draganov D, Gopalakrishna-Pillai S, Chen YR, Zuckerman N, Moeller S, Wang C, et al. . Modulation of P2x4/P2x7/pannexin-1 sensitivity to extracellular atp via ivermectin induces A non-apoptotic and inflammatory form of cancer cell death. Sci Rep. (2015) 5:16222. doi: 10.1038/srep16222</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep16222</ArticleId><ArticleId IdType="pmc">PMC4639773</ArticleId><ArticleId IdType="pubmed">26552848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Li K, Lin X, Yao Z, Wang S, Xiong X, et al. . Metformin induces human esophageal carcinoma cell pyroptosis by targeting the mir-497/pelp1 axis. Cancer Lett. (2019) 450:22–31. doi: 10.1016/j.canlet.2019.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2019.02.014</ArticleId><ArticleId IdType="pubmed">30771436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discovery. (2022) 21:529–40. doi: 10.1038/s41573-022-00493-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00493-5</ArticleId><ArticleId IdType="pubmed">35701637</ArticleId></ArticleIdList></Reference><Reference><Citation>D’elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the “Cytokine storm” For Therapeutic Benefit. Clin Vaccine Immunol. (2013) 20:319–27. doi: 10.1128/CVI.00636-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00636-12</ArticleId><ArticleId IdType="pmc">PMC3592351</ArticleId><ArticleId IdType="pubmed">23283640</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. (2012) 76:16–32. doi: 10.1128/MMBR.05015-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.05015-11</ArticleId><ArticleId IdType="pmc">PMC3294426</ArticleId><ArticleId IdType="pubmed">22390970</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb P, Molla MMA, Saif-Ur-Rahman KM. An update to monoclonal antibody as therapeutic option against covid-19. Biosaf Health. (2021) 3:87–91. doi: 10.1016/j.bsheal.2021.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bsheal.2021.02.001</ArticleId><ArticleId IdType="pmc">PMC7872849</ArticleId><ArticleId IdType="pubmed">33585808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Leaf DE. Tocilizumab in covid-19: some clarity amid controversy. Lancet. (2021) 397:1599–601. doi: 10.1016/S0140-6736(21)00712-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00712-1</ArticleId><ArticleId IdType="pmc">PMC8084409</ArticleId><ArticleId IdType="pubmed">33933194</ArticleId></ArticleIdList></Reference><Reference><Citation>Group RC. Tocilizumab in patients admitted to hospital with covid-19 (Recovery): A randomised, controlled, open-label, platform trial. Lancet. (2021) 397:1637–45. doi: 10.1016/S0140-6736(21)00676-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Droebner K, Reiling SJ, Planz O. Role of hypercytokinemia in nf-kappab P50-deficient mice after H5n1 influenza A virus infection. J Virol. (2008) 82:11461–6. doi: 10.1128/JVI.01071-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01071-08</ArticleId><ArticleId IdType="pmc">PMC2573282</ArticleId><ArticleId IdType="pubmed">18768968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M, Planz O. Nf-kappab pathway as A potential target for treatment of critical stage covid-19 patients. Front Immunol. (2020) 11:598444. doi: 10.3389/fimmu.2020.598444</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.598444</ArticleId><ArticleId IdType="pmc">PMC7759159</ArticleId><ArticleId IdType="pubmed">33362782</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasaraju T, Ravi Y, Jonsson CB, Chow VTK. High-dose corticosteroid therapy in covid-19: the recovery trial. Lancet. (2024) 403:1338–9. doi: 10.1016/S0140-6736(23)02884-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)02884-2</ArticleId><ArticleId IdType="pubmed">38582562</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappab- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation. (2005) 12:321–38. doi: 10.1159/000091126</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000091126</ArticleId><ArticleId IdType="pubmed">16557033</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Zhang S, Hu Y, Li D, Cui J, Xue J, et al. . Regulatory roles of C-jun in H5n1 influenza virus replication and host inflammation. Biochim Biophys Acta. (2014) 1842:2479–88. doi: 10.1016/j.bbadis.2014.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.04.017</ArticleId><ArticleId IdType="pubmed">24780373</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Zhang S, Wang S. Dnazymes dz13 target the C-jun possess antiviral activity against influenza A viruses. Microb Pathog. (2017) 103:155–61. doi: 10.1016/j.micpath.2016.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2016.12.024</ArticleId><ArticleId IdType="pubmed">28039102</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. . Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. (2006) 24:3113–20. doi: 10.1200/JCO.2005.04.7779</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2005.04.7779</ArticleId><ArticleId IdType="pubmed">16754936</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JA, Mckenzie ANJ. T(H)2 cell development and function. Nat Rev Immunol. (2018) 18:121–33. doi: 10.1038/nri.2017.118</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.118</ArticleId><ArticleId IdType="pubmed">29082915</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Pro-inflammatory and anti-inflammatory interleukins in infectious diseases: A comprehensive review. Trop Med Infect Dis. (2024) 9(1):13. doi: 10.3390/tropicalmed9010013</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed9010013</ArticleId><ArticleId IdType="pmc">PMC10818686</ArticleId><ArticleId IdType="pubmed">38251210</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva M, Vieira P, O’garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. (2020) 217(1):e20190418. doi: 10.1084/jem.20190418</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190418</ArticleId><ArticleId IdType="pmc">PMC7037253</ArticleId><ArticleId IdType="pubmed">31611251</ArticleId></ArticleIdList></Reference><Reference><Citation>Autio K, Oft M. Pegylated interleukin-10: clinical development of an immunoregulatory cytokine for use in cancer therapeutics. Curr Oncol Rep. (2019) 21:19. doi: 10.1007/s11912-019-0760-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-019-0760-z</ArticleId><ArticleId IdType="pubmed">30790069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez LA, Melo-Gonzalez F, Sebastian VP, Vallejos OP, Noguera LP, Suazo ID, et al. . Characterization of the anti-inflammatory capacity of il-10-producing neutrophils in response to streptococcus pneumoniae infection. Front Immunol. (2021) 12:638917. doi: 10.3389/fimmu.2021.638917</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.638917</ArticleId><ArticleId IdType="pmc">PMC8113954</ArticleId><ArticleId IdType="pubmed">33995357</ArticleId></ArticleIdList></Reference><Reference><Citation>Redford PS, Murray PJ, O’garra A. The role of il-10 in immune regulation during M. Tuberculosis infection. Mucosal Immunol. (2011) 4:261–70. doi: 10.1038/mi.2011.7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2011.7</ArticleId><ArticleId IdType="pubmed">21451501</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam H, Chamberlain TC, Mui AL, Little JP. Elevated interleukin-10 levels in covid-19: potentiation of pro-inflammatory responses or impaired anti-inflammatory action? Front Immunol. (2021) 12:677008. doi: 10.3389/fimmu.2021.677008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.677008</ArticleId><ArticleId IdType="pmc">PMC8255680</ArticleId><ArticleId IdType="pubmed">34234779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lama L, Adura C, Xie W, Tomita D, Kamei T, Kuryavyi V, et al. . Development of human cgas-specific small-molecule inhibitors for repression of dsdna-triggered interferon expression. Nat Commun. (2019) 10(1):2261. doi: 10.1038/s41467-019-08620-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-08620-4</ArticleId><ArticleId IdType="pmc">PMC6529454</ArticleId><ArticleId IdType="pubmed">31113940</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Xiong M, Yuan X, Li M, Sun H, Xu Y. In silico screening-based discovery of novel inhibitors of human cyclic gmp-amp synthase: A cross-validation study of molecular docking and experimental testing. J Chem Inf Model. (2020) 60:3265–76. doi: 10.1021/acs.jcim.0c00171</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.0c00171</ArticleId><ArticleId IdType="pubmed">32459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Z, Mei J, Li C, Bai G, Maimaiti M, Hu H, et al. . STING inhibitors target the cyclic dinucleotide binding pocket. Proc Natl Acad Sci USA. (2021) 118(24):e2105465118. doi: 10.1073/pnas.2105465118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2105465118</ArticleId><ArticleId IdType="pmc">PMC8214703</ArticleId><ArticleId IdType="pubmed">34099558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosli S, Harpur CM, Lam M, West AC, Hodges C, Mansell A, et al. . Gasdermin D promotes hyperinflammation and immunopathology during severe influenza A virus infection. Cell Death Dis. (2023) 14:727. doi: 10.1038/s41419-023-06258-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-023-06258-1</ArticleId><ArticleId IdType="pmc">PMC10636052</ArticleId><ArticleId IdType="pubmed">37945599</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Dong H, Wu C, Zhong Y, Li J. The role of nlrp3 inflammasome in sepsis: A potential therapeutic target. Int Immunopharmacol. (2023) 115:109697. doi: 10.1016/j.intimp.2023.109697</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.109697</ArticleId><ArticleId IdType="pubmed">37724951</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll RC, Schroder K, Pelegrin P. Nlrp3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. (2022) 43:653–68. doi: 10.1016/j.tips.2022.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2022.04.003</ArticleId><ArticleId IdType="pubmed">35513901</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker C, Mattes H, Wright M, Boettcher A, Hinniger A, Hughes N, et al. . Crystal structure of nlrp3 nacht domain with an inhibitor defines mechanism of inflammasome inhibition. J Mol Biol. (2021) 433:167309. doi: 10.1016/j.jmb.2021.167309</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.167309</ArticleId><ArticleId IdType="pubmed">34687713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tate MD, Ong JDH, Dowling JK, Mcauley JL, Robertson AB, Latz E, et al. . Reassessing the role of the nlrp3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci Rep. (2016) 6:27912. doi: 10.1038/srep27912</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep27912</ArticleId><ArticleId IdType="pmc">PMC4901306</ArticleId><ArticleId IdType="pubmed">27283237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, et al. . The immunomodulatory metabolite itaconate modifies nlrp3 and inhibits inflammasome activation. Cell Metab. (2020) 32:468–478.E7. doi: 10.1016/j.cmet.2020.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.07.016</ArticleId><ArticleId IdType="pmc">PMC7422798</ArticleId><ArticleId IdType="pubmed">32791101</ArticleId></ArticleIdList></Reference><Reference><Citation>Runtsch MC, Angiari S, Hooftman A, Wadhwa R, Zhang Y, Zheng Y, et al. . Itaconate and itaconate derivatives target jak1 to suppress alternative activation of macrophages. Cell Metab. (2022) 34:487–501.E8. doi: 10.1016/j.cmet.2022.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2022.02.002</ArticleId><ArticleId IdType="pubmed">35235776</ArticleId></ArticleIdList></Reference><Reference><Citation>Maassen S, Coenen B, Ioannidis M, Harber K, Grijpstra P, Van Den Bossche J, et al. . Itaconate promotes A wound resolving phenotype in pro-inflammatory macrophages. Redox Biol. (2023) 59:102591. doi: 10.1016/j.redox.2022.102591</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2022.102591</ArticleId><ArticleId IdType="pmc">PMC9800195</ArticleId><ArticleId IdType="pubmed">36574745</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Zheng W, Kong W, Zeng T. Itaconate: A potent macrophage immunomodulator. Inflammation. (2023) 46:1177–91. doi: 10.1007/s10753-023-01819-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-023-01819-0</ArticleId><ArticleId IdType="pmc">PMC10159227</ArticleId><ArticleId IdType="pubmed">37142886</ArticleId></ArticleIdList></Reference><Reference><Citation>Olagnier D, Farahani E, Thyrsted J, Blay-Cadanet J, Herengt A, Idorn M, et al. . SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. (2020) 11(1):4938. doi: 10.1038/s41467-020-18764-3. Erratum in: Nat Commun. 2020 Oct 21;11(1):5419. doi: 10.1038/s41467-020-19363-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18764-3</ArticleId><ArticleId IdType="pmc">PMC7532469</ArticleId><ArticleId IdType="pubmed">33009401</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair S, Huynh JP, Lampropoulou V, Loginicheva E, Esaulova E, Gounder AP, et al. . Irg1 expression in myeloid cells prevents immunopathology during M. Tuberculosis infection. J Exp Med. (2018) 215:1035–45. doi: 10.1084/jem.20180118</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180118</ArticleId><ArticleId IdType="pmc">PMC5881474</ArticleId><ArticleId IdType="pubmed">29511063</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts LM, Leighton I, Schwarz B, Wehrly TD, Evans TJ, Bosio CM. Itaconate indirectly influences expansion of effector T cells following vaccination with francisella tularensis live vaccine strain. Cell Immunol. (2022) 373:104485. doi: 10.1016/j.cellimm.2022.104485</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2022.104485</ArticleId><ArticleId IdType="pubmed">35149415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacey CA, Ponzilacqua-Silva B, Chambers CA, Dadelahi AS, Skyberg JA. Myd88-dependent glucose restriction and itaconate production control brucella infection. Infect Immun. (2021) 89:E0015621. doi: 10.1128/IAI.00156-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00156-21</ArticleId><ArticleId IdType="pmc">PMC8445166</ArticleId><ArticleId IdType="pubmed">34125603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohl L, Siddique M, Bodendorfer B, Berger R, Preikschat A, Daniel C, et al. . Macrophages inhibit coxiella burnetii by the acod1-itaconate pathway for containment of Q fever. EMBO Mol Med. (2023) 15:E15931. doi: 10.15252/emmm.202215931</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202215931</ArticleId><ArticleId IdType="pmc">PMC9906395</ArticleId><ArticleId IdType="pubmed">36479617</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoensup J, Sermswan RW, Paeyao A, Promakhejohn S, Punasee S, Chularari C, et al. . High hmgb1 level is associated with poor outcome of septicemic melioidosis. Int J Infect Dis. (2014) 28:111–6. doi: 10.1016/j.ijid.2014.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.07.025</ArticleId><ArticleId IdType="pubmed">25263503</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws TR, Clark GC, D’elia RV. Immune profiling of the progression of A balb/C mouse aerosol infection by burkholderia pseudomallei and the therapeutic implications of targeting hmgb1. Int J Infect Dis. (2015) 40:1–8. doi: 10.1016/j.ijid.2015.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2015.09.003</ArticleId><ArticleId IdType="pubmed">26358857</ArticleId></ArticleIdList></Reference><Reference><Citation>D’elia RV, Laws TR, Carter A, Lukaszewski R, Clark GC. Targeting the “Rising damp” During A francisella tularensis infection. Antimicrob Agents Chemother. (2013) 57:4222–8. doi: 10.1128/AAC.01885-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01885-12</ArticleId><ArticleId IdType="pmc">PMC3754292</ArticleId><ArticleId IdType="pubmed">23796927</ArticleId></ArticleIdList></Reference><Reference><Citation>Casulli J, Fife ME, Houston SA, Rossi S, Dow J, Williamson ED, et al. . CD200R deletion promotes A neutrophil niche for francisella tularensis and increases infectious burden and mortality. Nat Commun. (2019) 10(1):2121. doi: 10.1038/s41467-019-10156-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10156-6</ArticleId><ArticleId IdType="pmc">PMC6509168</ArticleId><ArticleId IdType="pubmed">31073183</ArticleId></ArticleIdList></Reference><Reference><Citation>Thom RE, Williamson ED, Casulli J, Butcher WA, Burgess G, Laws TR, et al. . Assessment of cd200r activation in combination with doxycycline in A model of melioidosis. Microbiol Spectr. (2023) 11:E0401622. doi: 10.1128/spectrum.04016-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.04016-22</ArticleId><ArticleId IdType="pmc">PMC10269878</ArticleId><ArticleId IdType="pubmed">37199641</ArticleId></ArticleIdList></Reference><Reference><Citation>Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, et al. . A critical function for cd200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol. (2008) 9:1074–83. doi: 10.1038/ni.1637</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1637</ArticleId><ArticleId IdType="pubmed">18660812</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Fan D, Lei Q, Lu A, He X. Roles of resolvins in chronic inflammatory response. Int J Mol Sci. (2022) 23(23):14883. doi: 10.3390/ijms232314883</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232314883</ArticleId><ArticleId IdType="pmc">PMC9738788</ArticleId><ArticleId IdType="pubmed">36499209</ArticleId></ArticleIdList></Reference><Reference><Citation>Centanni D, Henricks PAJ, Engels F. The therapeutic potential of resolvins in pulmonary diseases. Eur J Pharmacol. (2023) 958:176047. doi: 10.1016/j.ejphar.2023.176047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2023.176047</ArticleId><ArticleId IdType="pubmed">37742814</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde K, Yates RM, Purdy GE, Russell DG. Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev. (2007) 219:37–54. doi: 10.1111/j.1600-065X.2007.00547.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2007.00547.x</ArticleId><ArticleId IdType="pubmed">17850480</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsayed SSR, Gunosewoyo H. Tuberculosis: pathogenesis, current treatment regimens and new drug targets. Int J Mol Sci. (2023) 24(6):5202. doi: 10.3390/ijms24065202</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065202</ArticleId><ArticleId IdType="pmc">PMC10049048</ArticleId><ArticleId IdType="pubmed">36982277</ArticleId></ArticleIdList></Reference><Reference><Citation>Adikesavalu H, Gopalaswamy R, Kumar A, Ranganathan UD, Shanmugam S. Autophagy induction as A host-directed therapeutic strategy against mycobacterium tuberculosis infection. Medicina (Kaunas). (2021) 57(6):522. doi: 10.3390/medicina57060522</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57060522</ArticleId><ArticleId IdType="pmc">PMC8224563</ArticleId><ArticleId IdType="pubmed">34070995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Zhou X, Ou M, Fu X, Lin Q, Tao X, et al. . Berbamine promotes macrophage autophagy to clear mycobacterium tuberculosis by regulating the ros/ca(2+) axis. Mbio. (2023) 14:E0027223. doi: 10.1128/mbio.00272-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00272-23</ArticleId><ArticleId IdType="pmc">PMC10470588</ArticleId><ArticleId IdType="pubmed">37382506</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the evidence. Kidney Int. (2001) 59:3–16. doi: 10.1046/j.1523-1755.2001.00460.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2001.00460.x</ArticleId><ArticleId IdType="pubmed">11135052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mugume Y, Kazibwe Z, Bassham DC. Target of rapamycin in control of autophagy: puppet master and signal integrator. Int J Mol Sci. (2020) 21(21):8259. doi: 10.3390/ijms21218259</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218259</ArticleId><ArticleId IdType="pmc">PMC7672647</ArticleId><ArticleId IdType="pubmed">33158137</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt K, Bhagavathula M, Verma S, Timmins GS, Deretic VP, Ellner JJ, et al. . Rapamycin modulates pulmonary pathology in A murine model of mycobacterium tuberculosis infection. Dis Model Mech. (2021) 14(10):dmm049018. doi: 10.1242/dmm.049018</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.049018</ArticleId><ArticleId IdType="pmc">PMC8560501</ArticleId><ArticleId IdType="pubmed">34486033</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh DK, Bhaskar A, Pahuja I, Shaji A, Moitra B, Shi Y, et al. . Cotreatment with clofazimine and rapamycin eliminates drug-resistant tuberculosis by inducing polyfunctional central memory T-cell responses. J Infect Dis. (2023) 228:1166–78. doi: 10.1093/infdis/jiad214</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad214</ArticleId><ArticleId IdType="pubmed">37290049</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Wu Y, Zhou X, Qian J, Zhu W, Shu Y, et al. . Clinical efficacy of mtor inhibitors in solid tumors: A systematic review. Future Oncol. (2015) 11:1687–99. doi: 10.2217/fon.15.70</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon.15.70</ArticleId><ArticleId IdType="pubmed">26043220</ArticleId></ArticleIdList></Reference><Reference><Citation>Boni JP, Hug B, Leister C, Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol. (2009) 36 Suppl 3:S18–25. doi: 10.1053/j.seminoncol.2009.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2009.10.009</ArticleId><ArticleId IdType="pubmed">19963096</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Subbian S. Harnessing the mtor pathway for tuberculosis treatment. Front Microbiol. (2018) 9:70. doi: 10.3389/fmicb.2018.00070</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.00070</ArticleId><ArticleId IdType="pmc">PMC5797605</ArticleId><ArticleId IdType="pubmed">29441052</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmapriydarsini C, Mamulwar M, Mohan A, Shanmugam P, Gomathy NS, Mane A, et al. . Randomized trial of metformin with anti-tuberculosis drugs for early sputum conversion in adults with pulmonary tuberculosis. Clin Infect Dis. (2022) 75:425–34. doi: 10.1093/cid/ciab964</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab964</ArticleId><ArticleId IdType="pmc">PMC9427151</ArticleId><ArticleId IdType="pubmed">34849651</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster EM, Epple MW, Glaser KM, Mihlan M, Lucht K, Zimmermann JA, et al. . Tfeb induces mitochondrial itaconate synthesis to suppress bacterial growth in macrophages. Nat Metab. (2022) 4:856–66. doi: 10.1038/s42255-022-00605-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-022-00605-w</ArticleId><ArticleId IdType="pmc">PMC9314259</ArticleId><ArticleId IdType="pubmed">35864246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Chen C, Yang F, Zeng YX, Sun P, Liu P, et al. . Itaconate is A lysosomal inducer that promotes antibacterial innate immunity. Mol Cell. (2022) 82:2844–2857.E10. doi: 10.1016/j.molcel.2022.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2022.05.009</ArticleId><ArticleId IdType="pubmed">35662396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. (2018) 18:91–104. doi: 10.1038/nri.2017.112</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.112</ArticleId><ArticleId IdType="pmc">PMC5991909</ArticleId><ArticleId IdType="pubmed">28990586</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. . Immune checkpoint inhibitors in cancer therapy. Curr Oncol. (2022) 29:3044–60. doi: 10.3390/curroncol29050247</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol29050247</ArticleId><ArticleId IdType="pmc">PMC9139602</ArticleId><ArticleId IdType="pubmed">35621637</ArticleId></ArticleIdList></Reference><Reference><Citation>Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. . Enhancing siv-specific immunity in vivo by pd-1 blockade. Nature. (2009) 458:206–10. doi: 10.1038/nature07662</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07662</ArticleId><ArticleId IdType="pmc">PMC2753387</ArticleId><ArticleId IdType="pubmed">19078956</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng HT, Tsai HF, Liao HJ, Lin YJ, Chen L, Chen PJ, et al. . Pd-1 blockage reverses immune dysfunction and hepatitis B viral persistence in A mouse animal model. PloS One. (2012) 7:E39179. doi: 10.1371/journal.pone.0039179</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039179</ArticleId><ArticleId IdType="pmc">PMC3382233</ArticleId><ArticleId IdType="pubmed">22761734</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, et al. . Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (Pd-1). Proc Natl Acad Sci U.S.A. (2013) 110:15001–6. doi: 10.1073/pnas.1312772110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1312772110</ArticleId><ArticleId IdType="pmc">PMC3773803</ArticleId><ArticleId IdType="pubmed">23980172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tousif S, Singh Y, Prasad DV, Sharma P, Van Kaer L, Das G. T cells from programmed death-1 deficient mice respond poorly to mycobacterium tuberculosis infection. PloS One. (2011) 6:E19864. doi: 10.1371/journal.pone.0019864</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0019864</ArticleId><ArticleId IdType="pmc">PMC3093409</ArticleId><ArticleId IdType="pubmed">21589883</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. Cd4 T cells promote rather than control tuberculosis in the absence of pd-1-mediated inhibition. J Immunol. (2011) 186:1598–607. doi: 10.4049/jimmunol.1003304</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1003304</ArticleId><ArticleId IdType="pmc">PMC4059388</ArticleId><ArticleId IdType="pubmed">21172867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, et al. . Programmed death-1 (Pd-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U.S.A. (2010) 107:13402–7. doi: 10.1073/pnas.1007394107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1007394107</ArticleId><ArticleId IdType="pmc">PMC2922129</ArticleId><ArticleId IdType="pubmed">20624978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Anderson JL, Lewin SR. Getting the “Kill” Into “Shock and kill”: strategies to eliminate latent hiv. Cell Host Microbe. (2018) 23:14–26. doi: 10.1016/j.chom.2017.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2017.12.004</ArticleId><ArticleId IdType="pmc">PMC5990418</ArticleId><ArticleId IdType="pubmed">29324227</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Teh SS, Lau HLN, Xiao J, Mah SH. Retinoids as anti-cancer agents and their mechanisms of action. Am J Cancer Res. (2022) 12:938–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8984900</ArticleId><ArticleId IdType="pubmed">35411232</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SL, Shyu RY, Yeh MY, Jiang SY. Cloning and characterization of A novel retinoid-inducible gene 1(Rig1) deriving from human gastric cancer cells. Mol Cell Endocrinol. (2000) 159:15–24. doi: 10.1016/S0303-7207(99)00207-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0303-7207(99)00207-5</ArticleId><ArticleId IdType="pubmed">10687848</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg RK, Melchjorsen J, Rintahaka J, Diget E, Soby S, Horan KA, et al. . Genomic hiv rna induces innate immune responses through rig-I-dependent sensing of secondary-structured rna. PloS One. (2012) 7:E29291. doi: 10.1371/journal.pone.0029291</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029291</ArticleId><ArticleId IdType="pmc">PMC3250430</ArticleId><ArticleId IdType="pubmed">22235281</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, et al. . Stimulating the rig-I pathway to kill cells in the latent hiv reservoir following viral reactivation. Nat Med. (2016) 22:807–11. doi: 10.1038/nm.4124</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4124</ArticleId><ArticleId IdType="pmc">PMC5004598</ArticleId><ArticleId IdType="pubmed">27294875</ArticleId></ArticleIdList></Reference><Reference><Citation>Purssell A MM, Vulesevic B, Angel Jb. Retinoids: novel potential therapeutics in the pursuit of hiv-1 cure. Front Virol. (2022) 2. doi: 10.3389/fviro.2022.957124</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fviro.2022.957124</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash A, Aghlara-Fotovat S, Hernandez A, Scull C, Veiseh O. Clinical translation of immunomodulatory therapeutics. Adv Drug Delivery Rev. (2021) 176:113896. doi: 10.1016/j.addr.2021.113896</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.113896</ArticleId><ArticleId IdType="pmc">PMC8567306</ArticleId><ArticleId IdType="pubmed">34324885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward RA, Aghaeepour N, Bhattacharyya RP, Clish CB, Gaudilliere B, Hacohen N, et al. . Harnessing the potential of multiomics studies for precision medicine in infectious disease. Open Forum Infect Dis. (2021) 8:Ofab483. doi: 10.1093/ofid/ofab483</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab483</ArticleId><ArticleId IdType="pmc">PMC8598922</ArticleId><ArticleId IdType="pubmed">34805429</ArticleId></ArticleIdList></Reference><Reference><Citation>Epsi NJ, Powers JH, Lindholm DA, Mende K, Malloy A, Ganesan A, et al. . A machine learning approach identifies distinct early-symptom cluster phenotypes which correlate with hospitalization, failure to return to activities, and prolonged covid-19 symptoms. PloS One. (2023) 18:E0281272. doi: 10.1371/journal.pone.0281272</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281272</ArticleId><ArticleId IdType="pmc">PMC9910657</ArticleId><ArticleId IdType="pubmed">36757946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>